Metallothionein overexpression, a highly significant prognostic factor in thin melanoma [11]

Histopathology

Volumn 51, Issue 2, 2007, Pages 280-283

  Weinlich, G ^a   Zelger, B ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; METALLOTHIONEIN;

CANCER GROWTH; DIAGNOSTIC VALUE; DRUG RESISTANCE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH;

DISEASE-FREE SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; METALLOTHIONEIN; PROGNOSIS; PROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 34447513965     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02744.x     Document Type: Letter

References (33)

1. Berman DM. Lack of agreement on predictors for metastasizing thin melanomas. Histopathology 2006 48 217 219.
2. McKinnon JG, Yu XQ, McCarthy WH, Thompson JF. Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer 2003 98 1223 1231.
3. Balch CM, Soong SJ, Gershenwald JE et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 2001 19 3622 3634.
4. McCarthy WH, Shaw HM, McCarthy SW, Rivers JK, Thompson JF. Cutaneous melanomas that defy conventional prognostic indicators. Semin. Oncol. 1996 23 709 713.
5. Leiter U, Buettner PG, Eigentler TK, Garbe C. Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the German Dermatological Society. J. Clin. Oncol. 2004 22 3660 3667.
6. Gimotty PA, Guerry D, Ming ME et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J. Clin. Oncol. 2004 22 3668 3676.
7. Mansson-Brahme E, Carstensen J, Erhardt K, Lagerlof B, Ringborg U, Rutqvist LE. Prognostic factors in thin cutaneous malignant melanoma. Cancer 1994 73 2324 2332.
8. Finley JW, Gibbs JF, Rodriguez LM, Letourneau R, Driscoll D, Kraybill W. Pathologic and clinical features influencing outcome of thin cutaneous melanoma: correlation with newly proposed staging system. Am. Surg. 2000 66 527 531 discussion 531 532.
9. Zelger B, Hittmair A, Schir M et al. Immunohistochemically demonstrated metallothionein expression in malignant melanoma. Histopathology 1993 23 257 263.
10. Weinlich G, Bitterlich W, Mayr V, Fritsch PO, Zelger B. Metallothionein-overexpression as a prognostic factor for progression and survival in melanoma. A prospective study on 520 patients. Br. J. Dermatol. 2003 149 535 541.
11. Weinlich G, Eisendle K, Hassler E, Baltaci M, Fritsch P, Zelger B. Metallothionein overexpression as a highly significant prognostic factor in melanoma. A prospective study on 1270 patients. Br. J. Oncol. 2006 94 835 841.
12. Nath R, Kambadur R, Gulati S, Paliwal VK, Sharma M. Molecular aspects, physiological functions, and clinical significance of metallothioneins. Crit. Rev. Food Sci. Nutr. 1988 27 41 85.
13. Miles AT, Hawksworth GM, Beattie JH, Rodilla V. Induction, regulation, degradation, and biological significance of mammalian metallothioneins. Crit. Rev. Biochem. Mol. Biol. 2000 35 35 70.
14. Nordberg M, Nordberg GF. Toxicological aspects of metallothionein. Cell. Mol. Biol. 2000 46 451 463.
15. Simpkins CO. Metallothionein in human disease. Cell. Mol. Biol. 2000 46 465 488.
16. Hanada K, Sawamura D, Tamai K et al. Novel function of metallothionein in photoprotection: metallothionein-null mouse exhibits reduced tolerance against ultraviolet B injury in the skin. J. Invest. Dermatol. 1998 111 582 585.
17. Hansen C, Ablett E, Green A et al. Biphasic response of the metallothionein promoter to ultraviolet radiation in human melanoma cells. Photochem. Photobiol. 1997 65 550 555.
18. Reeve VE, Nishimura N, Bosnic M, Michalska AE, Choo KH. Lack of metallothionein-I and -II exacerbates the immunosuppressive effect of ultraviolet B radiation and cis-urocanic acid in mice. Immunology 2000 100 399 404.
19. Okazaki Y, Miura N, Satoh M, Imura N, Naganuma A. Metallothionein- mediated resistance to multiple drugs can be induced by several anticancer drugs in mice. Biochem. Biophys. Res. Commun. 1998 245 815 818.
20. Hishikawa Y, Abe S, Kinugasa S et al. Overexpression of metallothionein correlates with chemoresistance to cisplatin and prognosis in oesophageal cancer. Oncology 1997 54 342 347.
21. Chin JL, Banerjee D, Kadhim SA, Kontozoglou TE, Chauvin PJ, Cherian MG. Metallothionein in testicular germ cell tumours and drug resistance. Clinical correlation. Cancer 1993 72 3029 3035.
22. Sunada F, Itabashi M, Ohkura H, Okumura T. p53 negativity, CDC25B positivity, and metallothionein negativity are predictors of a response of esophageal squamous cell carcinoma to chemoradiotherapy. World J. Gastroenterol. 2005 11 5696 5700.
23. Tsangaris GT, Tzortzatou-Stathopoulou F. Metallothionein expression prevents apoptosis: a study with antisense phosphorothioate oligodeoxynucleotides in a human T cell line. Anticancer Res. 1998 18 2423 2434.
24. Surowiak P, Materna V, Kaplenko I et al. Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients. Virchows Arch. 2005 447 626 633.
25. Mitropoulos D, Kyroudi-Voulgari A, Theocharis S et al. Prognostic significance of metallothionein expression in renal cell carcinoma. World J. Surg. Oncol. 2005 3 5.
26. Dziegiel P, Jelen M, Muszczynska B et al. Role of metallothionein expression in non-small cell lung carcinomas. Rocz. Akad. Med. Bialymst 2004 49 43 45.
27. Sauerbrey A, Zintl F, Volm M. Expression of metallothionein in initial and relapsed childhood acute lymphoblastic leukemia. Ann. Hematol. 1994 69 111 115.
28. Ohshio G, Imamura T, Okada N et al. Immunohistochemical study of metallothionein in pancreatic carcinomas. J. Cancer Res. Clin. Oncol. 1996 122 351 355.
29. Shukla VK, Aryya NC, Pitale A et al. Metallothionein expression in carcinoma of the gallbladder. Histopathology 1998 33 154 157.
30. Zelger B, Sidoroff A, Höpfl R, Öfner D, Jasani B, Schmid KW. Metallothionein expression in nonmelanoma skin cancer. An immunohistochemical study. Appl. Immunohistochem. 1994 2 254 260.
31. Goldmann T, Ribbert D, Suter L, Brode M, Otto F. Tumour characteristics involved in the metastatic behaviour as an improvement in primary cutaneous melanoma prognostics. J. Exp. Clin. Cancer Res. 1998 17 483 489.
32. Sugita K, Yamamoto O, Asahi M. Immunohistochemical analysis of metallothionein expression in malignant melanoma in Japanese patients. Am. J. Dermatopathol. 2001 23 29 35.
33. Rossen K, Haerslev T, Hou-Jensen K, Jacobsen GK. Metallothionein expression in basaloid proliferations overlying dermatofibromas and in basal cell carcinomas. Br. J. Dermatol. 1997 136 30 34.